Jason Gotlib

5.0/5

65 Patient Ratings

372 Patient Reviews

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Hematology (2024)
Medical Education: Stanford University School of Medicine (1995) CA
Fellowship: Stanford University Hematology and Oncology Fellowship (2003) CA
- Residency: Stanford University Internal Medicine Residency (1998) CA
- Internship: Stanford University Internal Medicine Residency (1996) CA
- B.A., Franklin & Marshall College, Biology; HAPOS (1990)
- M.D., Stanford, Medicine (1995)
- M.S., Stanford, Clinical Epidemiology (2003)

View More Education & Certifications

Honors & Awards

Charles Dorsey Armstrong Award for Excellence in Patient Care, Stanford Internal Medicine Residency Program (1998)
Hematology Division Faculty Teaching Award, Stanford Division of Hematology/Department of Medicine (2005, 2007, 2009)
NIH K23 Mentored Patient-Oriented Research Career Development Award (#HL04409), National Institutes of Health (2001-2006)

Publications

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
Coutre, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. SEMINARS IN CANCER BIOLOGY, 14(1), 23鈥�31.
The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutre, S. E. (2004). The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. BLOOD, 103(8), 2879鈥�91.
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutr茅, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology, 14(4), 307鈥�15.
- Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
  Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., 鈥� Weissman, I. L. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. NEW ENGLAND JOURNAL OF MEDICINE, 351(7), 657鈥�67.
- Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
  Gotlib, J. (2005). Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Current Hematology Reports, 4(1), 77鈥�84.
- Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
  Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., 鈥� Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865鈥�70.
- Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
  Gotlib, J. (2005). Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. ACTA HAEMATOLOGICA, 114(1), 7鈥�25.
- Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy
  Gotlib, J., Cross, N. C. R., & Gilliland, D. G. (2006). Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 19(3), 535鈥�569.
- Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis
  Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., Schrijver, I., & Zehnder, J. L. (2006). Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. JOURNAL OF MOLECULAR DIAGNOSTICS, 8(3), 330鈥�34.
- A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance
  Fukumoto, J. S., & Gotlib, J. (2006). A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. AMERICAN JOURNAL OF HEMATOLOGY, 81(11), 870鈥�74.
- KIT mutations in mastocytosis and their potential as therapeutic targets
  Gotlib, J. (2006). KIT mutations in mastocytosis and their potential as therapeutic targets. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 26(3), 575-?
- Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system
  Dormady, S. P., Mariappan, M. R., Kao, D., & Gotlib, J. (2006). Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. JOURNAL OF CLINICAL ONCOLOGY, 24(27), 4515鈥�16.
- Gene expression and pathway analysis of immune thrombocytopenic purpura
  Sood, R., Wong, W., Gotlib, J., Jeng, M., & Zehnder, J. L. (2008). Gene expression and pathway analysis of immune thrombocytopenic purpura. BRITISH JOURNAL OF HAEMATOLOGY, 140(1), 99鈥�103.
- Chronic eosinophilic leukemia/hypereosinophilic syndrome.
  Gotlib, J. (2008). Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treatment and Research, 142, 69鈥�106.
- Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
  Geron, I., Abrahamsson, A. E., Barroga, C. F., Kavalerchik, E., Gotlib, J., Hood, J. D., 鈥� Jamieson, C. H. M. (2008). Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors. CANCER CELL, 13(4), 321鈥�330.
- Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
  Gotlib, J., & Cools, J. (2008). Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. LEUKEMIA, 22(11), 1999鈥�2010.
- A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
  Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15鈥�20.
- Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
  Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., 鈥� Arber, D. A. (2009). Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. BLOOD, 113(9), 1906鈥�8.
- Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation
  Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., Newton, I. G., 鈥� Jamieson, C. H. M. (2009). Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(10), 3925鈥�29.
- Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
  Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., 鈥� Felsher, D. W. (2009). Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. NATURE MEDICINE, 15(5), 566鈥�71.
- RNAi screen for rapid therapeutic target identification in leukemia patients
  Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., Willis, S. G., 鈥� Druker, B. J. (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(21), 8695鈥�8700.
- Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
  Korver, W., Zhao, X., Singh, S., Pardoux, C., Zhao, J., Guzman, M. L., 鈥� Abo, A. (2009). Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. LEUKEMIA, 23(9), 1587鈥�97.
- Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission
  Medeiros, B. C., Gotlib, J., & Zehnder, J. (2009). Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. LEUKEMIA & LYMPHOMA, 50(5), 851鈥�53.
- Novel biospecific agents for the treatment of myelodysplastic syndromes.
  Gotlib, J., & Greenberg, P. L. (2003). Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 1(4), 473鈥�80.
- When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings
  Pollyea, D. A., George, T. I., Corless, C., & Gotlib, J. (2009). When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 843鈥�46.
- On being metachromatic: mystique and misunderstanding in mastocytosis
  Gotlib, J. (2009). On being metachromatic: mystique and misunderstanding in mastocytosis. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 779鈥�81.
- Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory
  Merker, J. D., Jones, C. D., Oh, S. T., Schrijver, I., Gotlib, J., & Zehnder, J. L. (2010). Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory. JOURNAL OF MOLECULAR DIAGNOSTICS, 12(1), 58鈥�64.
- Eosinophilic myeloid disorders: new classification and novel therapeutic strategies
  Gotlib, J. (2010). Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. CURRENT OPINION IN HEMATOLOGY, 17(2), 117鈥�24.
- Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
  Hidalgo-Curtis, C., Apperley, J. F., Stark, A., Jeng, M., Gotlib, J., Chase, A., 鈥� Grand, F. H. (2010). Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 268鈥�73.
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
  Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., 鈥� Gotlib, J. (2010). Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. BLOOD, 116(6), 988鈥�92.
- Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
  Oh, S. T., & Gotlib, J. (2008). Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Current Hematologic Malignancy Reports, 3(1), 10鈥�18.
- Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
  Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., 鈥� George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600鈥�606.
- Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., 鈥� Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877鈥�81.
- JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
  Oh, S. T., & Gotlib, J. (2010). JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. EXPERT REVIEW OF HEMATOLOGY, 3(3), 323鈥�37.
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
  Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., 鈥� Tefferi, A. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 789鈥�796.
- World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
  Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 86(8), 677鈥�88.
- Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
  Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2011). Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. HEMATOLOGICAL ONCOLOGY, 29(3), 157鈥�60.
- Treatment advances have not improved the early death rate in acute promyelocytic leukemia
  McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133鈥�36.
- Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
  Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., 鈥� Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30鈥�37.
- Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
  Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., 鈥� Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893鈥�901.
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
  Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45鈥�50.
- A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.
  Zhang, B., Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., 鈥� Gotlib, J. (2011). A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood, 118(26), 6988鈥�90.
- Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders
  Gotlib, J., & Akin, C. (2012). Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders. SEMINARS IN HEMATOLOGY, 49(2), 128鈥�37.
- DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups
  Ohgami, R. S., Ma, L., Ren, L., Weinberg, O. K., Seetharam, M., Gotlib, J. R., & Arber, D. A. (2012). DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. BRITISH JOURNAL OF HAEMATOLOGY, 159(2), 182鈥�90.
- World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
  Gotlib, J. (2012). World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 87(9), 903鈥�14.
- Accessory splenules in autoimmune hemolytic anemia.
  Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. American Journal of Hematology, 88(2), 156-?
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
  Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., 鈥� Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591鈥�96.
- ICON: Eosinophil Disorders.
  Valent, P., Klion, A. D., Rosenwasser, L. J., Arock, M., Bochner, B. S., Butterfield, J. H., 鈥� Gleich, G. J. (2012). ICON: Eosinophil Disorders. The World Allergy Organization Journal, 5(12), 174鈥�81.
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
  Gotlib, J., Pardanani, A., Akin, C., Reiter, A., George, T., Hermine, O., 鈥� Valent, P. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. BLOOD, 121(13), 2393鈥�2401.
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
  Mesa, R. A., Gotlib, J., Gupta, V., Catalano, J. V., Deininger, M. W., Shields, A. L., 鈥� Verstovsek, S. (2013). Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(10), 1285鈥�1292.
- Next-generation sequencing in hematologic malignancies: what will be the dividends?
  Merker, J. D., Valouev, A., & Gotlib, J. (2012). Next-generation sequencing in hematologic malignancies: what will be the dividends? Therapeutic Advances in Hematology, 3(6), 333鈥�39.
- SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis
  Pardanani, A., Gotlib, J., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R., 鈥� Tefferi, A. (2011). SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis. BLOOD, 118(21), 1640鈥�1640.
- Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation
  Abrahamsson, A., Geron, I., Gotlib, J., Dao, K.-H., Giles, F., Newton, I., 鈥� Jamieson, C. H. M. (2007). Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation. BLOOD, 110(11), 238A鈥�239A.
- NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells
  Raval, A., Park, C. Y., Pang, W. W., Kusler, B., Sridhar, K. J., Gotlib, J. R., 鈥� Mitchell, B. S. (2009). NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells. BLOOD, 114(22), 307鈥�.
- Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
  McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., 鈥� George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA: NATURE PUBLISHING GROUP.
- Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. M. (2011). Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. BLOOD, 118(21), 128鈥�129.
- Whole Genome Sequence Analysis of Primary Myelofibrosis.
  Merker, J. D., Roskin, K., Ng, D., Pan, C., Fisk, D. G., Jones, C. D., 鈥� Gotlib, J. (2012). Whole Genome Sequence Analysis of Primary Myelofibrosis. BLOOD. ATLANTA,GA,GA,GA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.
- Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
  Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
- A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
  Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).
- Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
  Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., 鈥� Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357鈥�58.
- A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
  Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., 鈥� Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347鈥�47.
- Gene expression profile of idiopathic thrombocytopenic purpura (ITP) reveals elevated expression of interferon regulated genes.
  Sood, R., Wong, W., Gotlib, J., Jeng, M., & Zehnder, J. L. (2006). Gene expression profile of idiopathic thrombocytopenic purpura (ITP) reveals elevated expression of interferon regulated genes. BLOOD, 108(11), 211A鈥�211A.
- Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia
  Gotlib, J., Zhang, B., Jones, C. D., Riess, J., Wong, W. B., Simonds, E. F., 鈥� Zehnder, J. L. (2010). Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.
- A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
  Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., Wong, W., 鈥� Gotlib, J. (2011). A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. BLOOD, 118(26), 6988-?
- Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412)
  Kunder, C. A., DeAngelo, D. J., Gotlib, J. R., Gitana, G., Atwater, S. K., & George, T. I. (2012). Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412). Presented at the 101st Annual Meeting of United-States-and-Canadian-Academy-of-Pathology (USCAP), VANCOUVER,CANADA,CANADA: NATURE PUBLISHING GROUP.
- Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System
  Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J., 鈥� Arber, D. A. (2009). Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA,MA,MA,MA: NATURE PUBLISHING GROUP.
- Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: Does NPM1 identify a lower risk group?
  Weinberg, O., Merker, J., Beck, A., Seetharam, M., Gotlib, J., Zehnder, J., & Arber, D. A. (2008). Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: Does NPM1 identify a lower risk group? Presented at the 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DENVER,CO,CO,CO,CO: NATURE PUBLISHING GROUP.
- Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System
  Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J. D., 鈥� Arber, D. A. (2008). Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System. BLOOD, 112(11), 341鈥�42.
- Design and Validation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-type JAK2 Transcript Levels
  Merker, J. D., Jones, C. D., Oh, S. T., Khan, S., Schrijver, I., Gotlib, J., & Zehnder, J. L. (2008). Design and Validation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-type JAK2 Transcript Levels. JOURNAL OF MOLECULAR DIAGNOSTICS, 10(6), 581鈥�81.
- Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
  Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420鈥�21.
- Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders
  Oh, S. T., Zahn, J. M., Jones, C. D., Zhang, B., Loh, M. L., Kantarjian, H., 鈥� Gotlib, J. (2010). Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.
- Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients
  Nguyen, H. (M., Hinds, D. A., Barnholt, K. E., Kiefer, A. K., Do, C. B., Eriksson, N., 鈥� Mesa, R. A. (2012). Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients. BLOOD. ATLANTA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.
- FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience
  Nguyen, H. (M., Anh Pham, A., Perkins, C., Linder, A., Fechter, L., & Gotlib, J. (2012). FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience. BLOOD, 120(21).
- Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts
  Barnholt, K. E., Hinds, D. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., 鈥� Zehnder, J. L. (2012). Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts. BLOOD. ATLANTA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.
- BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor
  Goff, D., Smith, K. M., Shih, A. Y., Court-Recart, A., Sadarangani, A., Geron, I., 鈥� Jamieson, C. (2011). BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor. BLOOD, 118(21), 1176鈥�76.
- Inhibition of chronic myelogenous leukemia stem cells with novel wnt antagonists.
  Kavalerchik, E., Gotlib, J., Geron, I., Abrahamsson, A., Wrasidlo, W., Goff, D., 鈥� Jamieson, C. (2006). Inhibition of chronic myelogenous leukemia stem cells with novel wnt antagonists. BLOOD, 108(11), 74A鈥�75A.
- A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets
  Ohgami, R. S., Alcasid, M., Ren, L., Gotlib, J. R., & Arber, D. A. (2013). A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets. Presented at the 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), BALTIMORE,MD: NATURE PUBLISHING GROUP.
- Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update
  Tefferi, A., Gotlib, J., & Pardanani, A. (2010). Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. MAYO CLINIC PROCEEDINGS, 85(2), 158鈥�164.
- Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
  Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., 鈥� Tyner, J. W. (2013). Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. NEW ENGLAND JOURNAL OF MEDICINE, 368(19), 1781鈥�90.
- PTPN11 mutations are rare in adult patients with chronic myelomonocytic leukemia (CMML).
  Loh, M. L., Vattikuti, S., Reynolds, M. G., Cheng, J. W., Lee, C. M., Gotlib, J., & Beran, M. (2003). PTPN11 mutations are rare in adult patients with chronic myelomonocytic leukemia (CMML). BLOOD, 102(11), 328B鈥�328B.
- Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist.
  Geron, I., Barroga, C., Gotlib, J., Kavalerchik, E., Abrahamsson, A., Goff, D., 鈥� Jamieson, C. (2006). Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist. BLOOD, 108(11), 1033A鈥�1033A.
- Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells
  Abrahamsson, A., Geron, I., Gotlib, J., Durocher, J., Creusot, R., Kavalerchik, E., 鈥� Jamieson, C. (2006). Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells. BLOOD, 108(11), 605A鈥�605A.
- Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib
  Leu, H. S., Goff, D. J., Low-Marchelli, J., Recart, A. C. C., Smith, K. M., Ma, W., 鈥� Jamieson, C. (2012). Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib. BLOOD, 120(21).
- Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
  Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., 鈥� Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
- Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., 鈥� Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646鈥�47.
- The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial
  Gotlib, J., George, T. I., Corless, C., Linder, A., Ruddell, A., Akin, C., 鈥� Graubert, T. (2007). The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial. BLOOD, 110(11), 1035A鈥�1035A.
- Chronic Myelogenous Leukemia
  O'Brien, S., Abboud, C. N., Akhtari, M., Altman, J., Berman, E., DeAngelo, D. J., 鈥� Yunus, F. (2012). Chronic Myelogenous Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(1), 64鈥�110.
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
  Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., 鈥� Karp, J. E. (2007). A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. BLOOD, 109(4), 1387鈥�94.
- Chronic Myelogenous Leukemia
  O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., 鈥� Wetzler, M. (2009). Chronic Myelogenous Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7(9), 984鈥�1023.
- World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management
  Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 86(8), 678鈥�88.
- The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
  Gotlib, J., Maxson, J. E., George, T. I., & Tyner, J. W. (2013). The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood, 122(10), 1707鈥�11.
- Editorial.
  Gotlib, J. (2013). Editorial. Therapeutic Advances in Hematology, 4(4), 235鈥�236.
- Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22).
  Johnson, R. C., Savage, N. M., Chiang, T., Gotlib, J. R., Cherry, A. M., Arber, D. A., & George, T. I. (2013). Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22). American Journal of Clinical Pathology, 140(4), 525鈥�35.
- Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.
  Merker, J. D., Roskin, K. M., Ng, D., Pan, C., Fisk, D. G., King, J. J., 鈥� Gotlib, J. (2013). Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. Haematologica, 98(11), 1689鈥�96.
- A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia
  Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., 鈥� Karp, J. E. (2008). A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia. BLOOD, 111(5), 2589鈥�96.
- Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines
  O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., 鈥� Sundar, H. (2013). Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(11), 1327鈥�40.
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
  Goff, D. J., Recart, A. C., Sadarangani, A., Chun, H.-J., Barrett, C. L., Krajewska, M., 鈥� Jamieson, C. H. M. (2013). A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. CELL STEM CELL, 12(3), 316鈥�28.
- Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
  Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., 鈥� Klion, A. D. (2012). Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. EXPERT REVIEW OF HEMATOLOGY, 5(2), 157鈥�76.
- Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
  Valent, P., Klion, A. D., Horny, H.-P., Roufosse, F., Gotlib, J., Weller, P. F., 鈥� Gleich, G. J. (2012). Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 130(3), 607-?
- Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings.
  Weinberg, O. K., Ohgami, R. S., Ma, L., Seo, K., Ren, L., Gotlib, J. R., 鈥� Arber, D. A. (2014). Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. American Journal of Clinical Pathology, 142(2), 190鈥�95.
- Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study.
  Chan, S. M., Chadwick, J., Young, D. L., Holmes, E., & Gotlib, J. (2014). Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study. Hematology Reports, 6(2), 5466-?
- Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
  Tefferi, A., Abdel-Wahab, O., Cervantes, F., Crispino, J. D., Finazzi, G., Girodon, F., 鈥� Mughal, T. (2011). Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. BLOOD CANCER JOURNAL, 1.
- The serum tryptase test: an emerging robust biomarker in clinical hematology
  Valent, P., Sperr, W. R., Sotlar, K., Reiter, A., Akin, C., Gotlib, J., 鈥� Arock, M. (2014). The serum tryptase test: an emerging robust biomarker in clinical hematology. EXPERT REVIEW OF HEMATOLOGY, 7(5), 683鈥�90.
- Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal
  Valent, P., Sotlar, K., Sperr, W. R., Escribano, L., Yavuz, S., Reiter, A., 鈥� Horny, H.-P. (2014). Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ANNALS OF ONCOLOGY, 25(9), 1691鈥�1700.
- Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis
  Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., 鈥� Arock, M. (2014). Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. ALLERGY, 69(10), 1267鈥�74.
- Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
  Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2015). Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. MODERN PATHOLOGY, 28(5), 706鈥�14.
- Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
  Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., 鈥� Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441鈥�45.
- Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology
  O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., 鈥� Sundar, H. (2014). Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(11), 1590鈥�1609.
- Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry
  Chisholm, K. M., Merker, J. D., Gotlib, J. R., Gitana, G., Lefterova, M., Zehnder, J. L., 鈥� Ohgami, R. S. (2015). Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 143(4), 527鈥�34.
- Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
  Stein, B. L., Gotlib, J., Arcasoy, M., Nguyen, M. H., Shah, N., Moliterno, A., 鈥� Mesa, R. A. (2015). Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 424鈥�34.
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100(4), 479鈥�88.
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
  Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., 鈥� Mesa, R. A. (2014). Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. ONCOTARGETS AND THERAPY, 7, 13鈥�21.
- CME Information: World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management
  Gotlib, J. (2014). CME Information: World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 89(3), 325鈥�37.
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. M. (2012). A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. NEW ENGLAND JOURNAL OF MEDICINE, 366(9), 799鈥�807.
- Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
  Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J., 鈥� Loriaux, M. M. (2013). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. CANCER RESEARCH, 73(1), 285鈥�96.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
  Mesa, R. A., Kiladjian, J.-J., Verstovsek, S., Al-Ali, H. K., Gotlib, J., Gisslinger, H., 鈥� Harrison, C. (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. HAEMATOLOGICA, 99(2), 292鈥�298.
- Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
  Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., 鈥� Greenberg, P. (2002). Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. LEUKEMIA, 16(2), 162鈥�64.
- KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
  Gleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hoermann, G., Rix, U., Bennett, K. L., 鈥� Valent, P. (2011). KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. BLOOD, 118(7), 1885鈥�1898.
- JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside
  Gotlib, J. (2013). JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 529鈥�537.
- Hereditary erythrocytosis, thrombocytosis and neutrophilia
  Hong, W.-J., & Gotlib, J. (2014). Hereditary erythrocytosis, thrombocytosis and neutrophilia. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 27(2), 95鈥�106.
- Practical management of patients with myelofibrosis receiving ruxolitinib
  Harrison, C., Mesa, R., Ross, D., Mead, A., Keohane, C., Gotlib, J., & Verstovsek, S. (2013). Practical management of patients with myelofibrosis receiving ruxolitinib. EXPERT REVIEW OF HEMATOLOGY, 6(5), 511鈥�523.
- LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
  Pardanani, A., Lasho, T., Finke, C., Oh, S. T., Gotlib, J., & Tefferi, A. (2010). LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. LEUKEMIA, 24(10), 1713鈥�1718.
- Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance
  Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., 鈥� Lane, A. A. (2015). Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. NATURE MEDICINE, 21(1), 71鈥�75.
- Myeloid and lymphoid Neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges
  Savage, N. M., Johnson, R. C., Gotlib, J., & George, T. I. (2013). Myeloid and lymphoid Neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges. AMERICAN JOURNAL OF HEMATOLOGY, 88(5), 427鈥�430.
- Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review
  Savage, N., George, T. I., & Gotlib, J. (2013). Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 35(5), 491鈥�500.
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. M. (2013). The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(4), 508鈥�516.
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
  Tefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A. M., 鈥� Barosi, G. (2013). Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 122(8), 1395鈥�1398.
- Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review
  Ustun, C., Savage, N. M., Gotlib, J., Bhalla, K., Manaloor, E., & George, T. I. (2012). Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review. AMERICAN JOURNAL OF HEMATOLOGY, 87(2), 191鈥�193.
- Altered translation of GATA1 in Diamond-Blackfan anemia
  Ludwig, L. S., Gazda, H. T., Eng, J. C., Eichhorn, S. W., Thiru, P., Ghazvinian, R., 鈥� Sankaran, V. G. (2014). Altered translation of GATA1 in Diamond-Blackfan anemia. NATURE MEDICINE, 20(7), 748鈥�53.
- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
  Abdel-Wahab, O., Pardanani, A., Bernard, O. A., Finazzi, G., Crispino, J. D., Gisslinger, H., 鈥� Tefferi, A. (2012). Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium. AMERICAN JOURNAL OF HEMATOLOGY, 87(5), 562鈥�568.
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. M. (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. HAEMATOLOGICA, 98(12), 1865鈥�1871.
- Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis
  Gupta, V., Gotlib, J., Radich, J. P., Kroeger, N. M., Rondelli, D., Verstovsek, S., & Deeg, H. J. (2014). Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(9), 1274鈥�81.
- Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
  Liedtke, M., Dunn, T., Dinner, S., Coutr茅, S. E., Berube, C., Gotlib, J., 鈥� Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441鈥�45.
- Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
  Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., 鈥� Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947鈥�50.
- KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
  Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., 鈥� Valent, P. (2015). KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. LEUKEMIA, 29(6), 1223鈥�1232.
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. HAEMATOLOGICA, 100(4), 482鈥�91.
- Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
  Mesa, R. A., Verstoysek, S., Gupta, V., Mascarenhas, J. O., Atallah, E., Burn, T., 鈥� Gotlib, J. (2015). Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15(4), 214鈥�221.
- Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
  Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., 鈥� Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609鈥�15.
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
  Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., 鈥� Verstovsek, S. (2015). Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. LEUKEMIA & LYMPHOMA, 56(7), 2092鈥�2097.
- The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
  Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., 鈥� Tyner, J. W. (2016). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research , 22(3), 757鈥�64.
- Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis
  Gotlib, J. (2015). Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 10(4), 351鈥�61.
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
  Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., 鈥� Verstovsek, S. (2015). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. HAEMATOLOGICA, 100(9), 1139鈥�45.
- Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
  Jamieson, C., Hasserjian, R., Gotlib, J., Cortes, J., Stone, R., Talpaz, M., 鈥� Pozdnyakova, O. (2015). Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. JOURNAL OF TRANSLATIONAL MEDICINE, 13.
- Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
  Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., 鈥� Valent, P. (2016). Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 137(1), 35鈥�45.
- A phase 1, open-label, dose-escalation study of pralatrexate in听combination with bortezomib in patients with relapsed/refractory multiple myeloma.
  Dunn, T. J., Dinner, S., Price, E., Coutr茅, S. E., Gotlib, J., Hao, Y., 鈥� Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in听combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253鈥�59.
- Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
  Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., 鈥� Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609鈥�15.
- Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
  Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., 鈥� Shannon, K. M. (2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. BLOOD, 103(6), 2325鈥�31.
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
  Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., 鈥� Mesa, R. A. (2013). Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 7, 13鈥�21.
- Insights into the molecular genetics of myeloproliferative neoplasms.
  Nguyen, H. M., & Gotlib, J. (2012). Insights into the molecular genetics of myeloproliferative neoplasms. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 411鈥�18.
- NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
  O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., 鈥� Wetzler, M. (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 7(9), 984鈥�1023.
- Age-related mutations and chronic myelomonocytic leukemia
  Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., 鈥� Deininger, M. W. (2016). Age-related mutations and chronic myelomonocytic leukemia. LEUKEMIA, 30(4), 906鈥�13.
- Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
  Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., 鈥� Reiter, A. (2016). Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEW ENGLAND JOURNAL OF MEDICINE, 374(26), 2530鈥�41.
- Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
  Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., 鈥� Gotlib, J. (2016). Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood, 128(8), 1121鈥�28.
- Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.
  Alvarez-Twose, I., Mart铆nez-Barranco, P., Gotlib, J., Garc铆a-Montero, A., Morgado, J. M., Jara-Acevedo, M., 鈥� Orfao, A. (2016). Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia, 30(8), 1753鈥�1756.
- Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
  Ustun, C., Arock, M., Kluin-Nelemans, H. C., Reiter, A., Sperr, W. R., George, T., 鈥� Valent, P. (2016). Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica, 101(10), 1133鈥�43.
- The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.
  Alcasid, M., Ma, L., Gotlib, J. R., Arber, D. A., & Ohgami, R. S. (2017). The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. International Journal of Laboratory Hematology.
- NCCN Guidelines (R) Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
  Pallera, A., Altman, J. K., Berman, E., Abboud, C. N., Bhatnagar, B., Curtin, P., 鈥� Radich, J. P. (2016). NCCN Guidelines (R) Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(12), 1505鈥�12.
- Myeloproliferative Neoplasms, Version 2.2017
  Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., 鈥� Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(12), 1572鈥�1611.
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
  Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., 鈥� Kantarjian, H. (2017). Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology & Oncology, 10(1), 55-?
- Chronic Myelogenous Leukemia, Version 1.2014.
  O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., 鈥� Sundar, H. (2013). Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network , 11(11), 1327鈥�40.
- Chronic myelogenous leukemia, version 1.2015.
  O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., 鈥� Sundar, H. (2014). Chronic myelogenous leukemia, version 1.2015. Journal of the National Comprehensive Cancer Network , 12(11), 1590鈥�1610.
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
  Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., 鈥� Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 14(12), 1572鈥�1611.
- Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
  Valent, P., Sotlar, K., Blatt, K., Hartmann, K., Reiter, A., Sadovnik, I., 鈥� Arock, M. (2017). Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia.
- Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
  Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., 鈥� Metcalfe, D. D. (2017). Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research.
- A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
  Verstovsek, S., Savona, M. R., Mesa, R. A., Dong, H., Maltzman, J. D., Sharma, S., 鈥� Gotlib, J. (2017). A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. British Journal of Haematology.
- How I treat atypical chronic myeloid leukemia
  Gotlib, J. (2017). How I treat atypical chronic myeloid leukemia. BLOOD, 129(7), 838鈥�45.
- Myeloid neoplasms with eosinophilia
  Reiter, A., & Gotlib, J. (2017). Myeloid neoplasms with eosinophilia. BLOOD, 129(6), 704鈥�14.
- Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens
  Shoura, M., Gabdank, I., Merker, J., Gotlib, J., Levene, S., & Fire, A. (2017). Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens. G3: GENES, GENOMES, GENETICS , 7, 3295鈥�3303.
- The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia
  Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., & Ohgami, R. (2017). The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia. LABORATORY INVESTIGATION, 97, 358A鈥�359A.
- A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia
  Chung, A., Hou, Y., Ohgami, R. S., Von Gehr, A., Fisk, D. G., Roskin, K. M., 鈥� Merker, J. D. (2017). A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. CANCER GENETICS, 216, 10鈥�15.
- The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia
  Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., & Ohgami, R. (2017). The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia. MODERN PATHOLOGY, 30, 358A鈥�359A.
- Variability of PD-L1 expression in mastocytosis
  Hatch, E. W., Geeze, M. B., Martin, C., Salama, M. E., Hartmann, K., Eisenwort, G., 鈥� George, T. I. (2018). Variability of PD-L1 expression in mastocytosis. BLOOD ADVANCES, 2(3), 189鈥�99.
- Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal
  Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., 鈥� Horny, H.-P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBIOMEDICINE, 26, 17鈥�24.
- Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist
  Shih, A. Y., Schairer, A., Barrett, C. L., Geron, I., Recart, A. C. C., Goff, D., 鈥� Jamieson, C. (2011). Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist. BLOOD, 118(21), 1613.
- The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings
  Segal, J., Dahl, G., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings. MODERN PATHOLOGY, 30, 376A.
- Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study
  Segal, J., Lacayo, N., Gotlib, J., & Ohgamt, R. (2017). Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study. MODERN PATHOLOGY, 30, 376A.
- A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study
  Segal, J., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study. LABORATORY INVESTIGATION, 97, 376A.
- The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings
  Segal, J., Dahl, G., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings. LABORATORY INVESTIGATION, 97, 376A.
- Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia
  Ustun, C., Williams, S., Skendzel, S., Kodal, B., Arock, M., Gotlib, J., 鈥� Miller, J. (2017). Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 92(5), E66鈥揈68.
- The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations
  Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., & Ohgami, R. (2018). The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations. MODERN PATHOLOGY, 31, 529.
- Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
  Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD. AMER SOC HEMATOLOGY.
- Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy
  Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., 鈥� Medeiros, B. C. (2012). Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. BLOOD. AMER SOC HEMATOLOGY.
- GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition
  Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., 鈥� Lane, A. A. (2014). GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. BLOOD, 124(21).
- A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
  Dinner, S., Dunn, T. J., Price, E., Coutr茅, S. E., Gotlib, J., Berube, C., 鈥� Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology.
- Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
  Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J., Ritchie, E. K., 鈥� Gotlib, J. R. (2014). Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
  Mesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., 鈥� Gotlib, J. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017734418.
- Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis
  Yun, H. D., Felices, M., Vallera, D. A., Cooley, S., Gotlib, J. R., Ustun, C., & Miller, J. S. (2018). Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S148鈥揝149.
- Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
  Mughal, T. I., Gotlib, J., Mesa, R., Koschmieder, S., Khoury, H. J., Cortes, J. E., 鈥� Abdel-Wahab, O. (2018). Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. LEUKEMIA RESEARCH, 67, 67鈥�74.
- Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics
  Ma, V. T., Boonstra, P. S., Menghrajani, K., Perkins, C., Gowin, K. L., Mesa, R. A., 鈥� Talpaz, M. (2018). Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(5), E201鈥揈210.
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
  Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., 鈥� Verstovsek, S. (2018). Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial. JAMA ONCOLOGY, 4(5), 652鈥�59.
- Myelophthisic marrow involved by breast cancer and acute myeloid leukemia
  Shomali, W., & Gotlib, J. (2018). Myelophthisic marrow involved by breast cancer and acute myeloid leukemia. BLOOD, 131(9), 1036.
- SOHO State-of-the-Art Update and Next Questions: MPN
  Bose, P., Gotlib, J., Harrison, C. N., & Verstovsek, S. (2018). SOHO State-of-the-Art Update and Next Questions: MPN. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(1), 1鈥�12.
- Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
  Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2018). Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. LEUKEMIA RESEARCH, 69, 100鈥�102.
- Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
  Yun, H. D., Felices, M., Vallera, D. A., Hinderlie, P., Cooley, S., Arock, M., 鈥� Miller, J. S. (2018). Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. BLOOD ADVANCES, 2(13), 1580鈥�84.
- Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
  Baird, J. H., & Gotlib, J. (2018). Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. Current Hematologic Malignancy Reports.
- Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia.
  Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Mignea, A., & Zehnder, J. (2008). Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia. BLOOD, 112(11), 351.
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
  Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2018). Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. HAEMATOLOGICA, 103(9), E392鈥揈394.
- Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
  Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., 鈥� Sundar, H. (2018). Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(9), 1108鈥�35.
- Mast cell activation syndrome: Importance of consensus criteria and call for 糖心传媒
  Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., 鈥� Metcalfe, D. D. (2018). Mast cell activation syndrome: Importance of consensus criteria and call for 糖心传媒. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 142(3), 1008-+.
- Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
  Dao, K.-H. T., Tyner, J. W., & Gotlib, J. (2017). Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 12(5), 432鈥�41.
- World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management
  Gotlib, J. (2017). World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 92(11), 1243鈥�59.
- NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
  Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., 鈥� Sundar, H. (2017). NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(10), 1193鈥�1207.
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
  Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., 鈥� Gupta, V. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. JOURNAL OF HEMATOLOGY & ONCOLOGY, 10, 156.
- Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis
  Gotlib, J. (2017). Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 31(4), 643-+.
- A molecular roadmap for midostaurin in mastocytosis
  Gotlib, J. (2017). A molecular roadmap for midostaurin in mastocytosis. BLOOD, 130(2), 98鈥�100.
- Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes
  Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., & Geoige, T. (2017). Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes. MODERN PATHOLOGY, 30, 378A.
- Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease
  Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., 鈥� George, T. (2017). Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease. MODERN PATHOLOGY, 30, 345A.
- Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes
  Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., & George, T. (2017). Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes. LABORATORY INVESTIGATION, 97, 378A.
- Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease
  Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., 鈥� George, T. (2017). Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease. LABORATORY INVESTIGATION, 97, 345A.
- Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)
  Sperr, W. R., Kundi, M., Elberink, H. O., van Anrooij, B., Gleixner, K. V., Hadzijusufovic, E., 鈥� Valent, P. (2016). Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry). BLOOD, 128(22).
- Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
  Ustun, C., Gotlib, J., Popat, U., Artz, A., Litzow, M., Reiter, A., 鈥� Valent, P. (2016). Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(8), 1348鈥�56.
- To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
  Menghrajani, K., Boonstra, P. S., Weber, A., Perkins, C., Gowin, K., Huong Nguyen, 鈥� Talpaz, M. (2015). To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, S236.
- PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis
  Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., 鈥� George, T. I. (2016). PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis. MODERN PATHOLOGY, 29, 346A.
- PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
  Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., 鈥� Gotlib, J. (2015). PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. BLOOD, 126(23).
- A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis
  Verstovsek, S., Savona, M. R., Mesa, R. A., Oh, S., Dong, H., Thai, D., & Gotlib, J. (2015). A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. BLOOD. AMER SOC HEMATOLOGY.
- PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis
  Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., 鈥� George, T. I. (2016). PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis. LABORATORY INVESTIGATION, 96, 346A.
- World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management
  Gotlib, J. (2015). World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 90(11), 1078鈥�89.
- A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
  Sasaki, K., Gotlib, J. R., Mesa, R. A., Ravandi, F., Cortes, J. E., Kelly, P. F., 鈥� Verstovsek, S. (2014). A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Eosinophilic myeloproliferative disorders
  Gotlib, J. (2014). Eosinophilic myeloproliferative disorders. CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE, 167鈥�75.
- A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers
  Kamal, M., Boonstra, P. S., Weber, A. A., Perkins, C., Gowin, K. L., Huong (Marie) Nguyen, 鈥� Talpaz, M. (2014). A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers. BLOOD, 124(21).
- A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)
  Passamonti, F., Alessandro, V., Domenica, C., Alessandro, R., Enrica, M., Jacques, K. J., 鈥� Cazzola, M. (2014). A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). BLOOD, 124(21).
- Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial
  Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., 鈥� Reiter, A. (2014). Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. BLOOD, 124(21).
- Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival
  Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Pomicter, A. D., Iovino, A. J., 鈥� Deininger, M. W. (2014). Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival. BLOOD, 124(21).
- Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
  Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., 鈥� Gotlib, J. R. (2014). Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. BLOOD, 124(21).
- Two faces of ET: CALR and JAK2
  Chao, M. P., & Gotlib, J. (2014). Two faces of ET: CALR and JAK2. BLOOD, 123(10), 1438鈥�40.
- Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
  Verstovsek, S., Mesa, R. A., Gotlib, J. R., Gupta, V., DiPersio, J. F., Catalano, J. V., 鈥� Kantarjian, H. (2012). Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I
  Mesa, R. A., Verstovsek, S., Gupta, V., Mascarenhas, J., Atallah, E., Sun, W., 鈥� Gotlib, J. (2012). Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. BLOOD, 120(21).
- Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms
  Mesa, R. A., Gotlib, J., Kantarjian, H. M., Sun, W., & Verstovsek, S. (2012). Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms. BLOOD, 120(21).
- Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials
  Verstovsek, S., Kiladjian, J.-J., Mesa, R. A., Vannucchi, A. M., Gotlib, J., Barosi, G., 鈥� Harrison, C. N. (2012). Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials. BLOOD. AMER SOC HEMATOLOGY.
- Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
  Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., 鈥� Tefferi, A. (2012). Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. BLOOD, 120(21).
- A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms
  Hinds, D. A., Barnholt, K. E., Zehnder, J. L., Kiefer, A. K., Do, C. B., Eriksson, N., 鈥� Gotlib, J. (2012). A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms. BLOOD. AMER SOC HEMATOLOGY.
- Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
  Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., 鈥� Kantarjian, H. M. (2012). Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. BLOOD, 120(21).
- KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial
  Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., 鈥� Reiter, A. (2012). KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. BLOOD, 120(21).
- An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis
  Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., 鈥� Tefferi, A. (2011). An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis. BLOOD, 118(21), 1645.
- Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF
  Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J., Deininger, M. W., 鈥� Verstovsek, S. (2011). Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF. BLOOD, 118(21), 1642鈥�43.
- A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes
  Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2010). A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. BLOOD, 116(21), 788.
- Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden
  Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., 鈥� Tefferi, A. (2010). Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden. BLOOD, 116(21), 205鈥�6.
- KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial
  Gotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., 鈥� Graubert, T. (2010). KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. BLOOD, 116(21), 144.
- Eosinophilic Disorders: Differential Diagnosis and Management
  Gotlib, J. (2011). Eosinophilic Disorders: Differential Diagnosis and Management. MYELOPROLIFERATIVE NEOPLASMS- BIOLOGY AND THERAPY, 181鈥�203.
- RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies
  Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B. H., Bicocca, V. T., Oh, S. T., 鈥� Druker, B. J. (2009). RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY.
- AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.
  Seetharam, M., Weinberg, O. K., Ren, L., Ma, L., Seo, K., Zehnder, J. L., 鈥� Arber, D. A. (2009). AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome. BLOOD, 114(22), 1035.
- A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden
  Pardanani, A. D., Gotlib, J. R., Jamieson, C., Cortes, J., Talpaz, M., Stone, R., 鈥� Tefferi, A. (2009). A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. BLOOD, 114(22), 314鈥�15.
- Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis
  Tyner, J. W., Fletcher, L., Yang, W., Oh, S. T., Gotlib, J. R., Deininger, M. W. N., 鈥� Loriaux, M. (2009). Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. BLOOD. AMER SOC HEMATOLOGY.
- Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis.
  Tyner, J. W., Erickson, H., Oh, S., Gotlib, J. R., Deininger, M. W. N., Druker, B. J., & Loriaux, M. (2008). Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis. BLOOD. AMER SOC HEMATOLOGY.
- RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients
  Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B., Bicocca, V. T., Oh, S., 鈥� Druker, B. J. (2008). RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients. BLOOD. AMER SOC HEMATOLOGY.
- A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis
  Pardanani, A. D., Gotlib, J., Jamieson, C., Cortes, J., Talpaz, M., Stone, R. M., 鈥� Tefferi, A. (2008). A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis. BLOOD, 112(11), 43鈥�44.
- Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit)
  Ustun, C., Morgan, E., Moodie, E. E. M., Pullarkat, S., Yeung, C., Broesby-Olsen, S., 鈥� Borthakur, G. (2018). Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit). CANCER MEDICINE, 7(9), 4447鈥�55.
- THE NUMBER AND TYPE OF MUTATIONS IN CANCER-LINKED GENES IS ASSOCIATED WITH OUTCOME OF SYSTEMIC MASTOCYTOSIS.
  Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Henriques, A., 鈥� Garcia-Montero, A. C. (2018). THE NUMBER AND TYPE OF MUTATIONS IN CANCER-LINKED GENES IS ASSOCIATED WITH OUTCOME OF SYSTEMIC MASTOCYTOSIS. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 40, 102.
- PLATELET TRANSCRIPTOMIC SIGNATURES IN MYELOPROLIFERATIVE NEOPLASMS
  Krishnan, A., Perkins, C., Gotlib, J., & Zehnder, J. (2018). PLATELET TRANSCRIPTOMIC SIGNATURES IN MYELOPROLIFERATIVE NEOPLASMS. AMERICAN JOURNAL OF HEMATOLOGY, 93(9), E34.
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
  Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2018). Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 8(10), 89.
- Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
  Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Hou, Y., 鈥� Garcia-Montero, A. C. (2018). Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Advances, 2(21), 2814鈥�28.
- The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.
  Valent, P., Oude Elberink, J. N., Gorska, A., Lange, M., Zanotti, R., van Anrooij, B., 鈥� Sperr, W. R. (2018). The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. The Journal of Allergy and Clinical Immunology. In Practice.
- The new tool "KIT" in advanced systemic mastocytosis.
  Shomali, W., & Gotlib, J. (2018). The new tool "KIT" in advanced systemic mastocytosis. Hematology. American Society of Hematology. Education Program, 2018(1), 127鈥�36.
- Systemic Mastocytosis, Version 2.2019
  Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., 鈥� Sundar, H. (2018). Systemic Mastocytosis, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(12), 1500鈥�1537.
- Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome.
  Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., 鈥� Metcalfe, D. D. (2019). Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome. The Journal of Allergy and Clinical Immunology. In Practice.
- Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
  Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., 鈥� Ohgami, R. S. (2019). Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. International Journal of Laboratory Hematology.
- Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells
  Chae, H.-D., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E. A., Abidi, P., 鈥� Sakamoto, K. M. (2018). Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells. BLOOD. AMER SOC HEMATOLOGY.
- Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
  Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2018). Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. BLOOD, 132.
- Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin
  Ediriwickrema, A., DeAngelo, D. J., George, T. I., Rosenberg-Hasson, Y., Perkins, C., Langford, C., & Gotlib, J. R. (2018). Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin. BLOOD, 132.
- Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
  Dao, K.-H., Collins, R. H., Cortes, J. E., Deininger, M. W., Druker, B. J., Gotlib, J. R., 鈥� Winton, E. F. (2018). Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY.
- Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)
  Gotlib, J. R., Radia, D., DeAngelo, D. J., Bose, P., Drummond, M. W., Hexner, E. O., 鈥� Deininger, M. W. (2018). Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). BLOOD, 132.
- Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)
  Verstovsek, S., Vannucchi, A. M., Rambaldi, A., Gotlib, J. R., Mead, A. J., Hochhaus, A., 鈥� Reiter, A. (2018). Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). BLOOD, 132.
- A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
  Masarova, L., Verstovsek, S., Hidalgo-Lopez, J. E., Pemmaraju, N., Bose, P., Estrov, Z., 鈥� Daver, N. (2018). A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. BLOOD, 132(16), 1664鈥�74.
- Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis
  Menghrajani, K., Boonstra, P. S., Mercer, J. A., Perkins, C., Gowin, K. L., Weber, A. A., 鈥� Talpaz, M. (2019). Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. LEUKEMIA & LYMPHOMA, 60(4), 1036鈥�42.
- Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.
  Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., 鈥� Horny, H.-P. P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 26, 17鈥�24.
- Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.
  Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., 鈥� Valent, P. (2016). Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. The Journal of Allergy and Clinical Immunology, 137(1), 35鈥�45.
- Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens.
  Shoura, M. J., Gabdank, I., Hansen, L., Merker, J., Gotlib, J., Levene, S. D., & Fire, A. Z. (2017). Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens. G3 (Bethesda, Md.), 7(10), 3295鈥�3303.
- Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms.
  Mughal, T. I., Pemmaraju, N., Radich, J. P., Deininger, M. W., Kucine, N., Kiladjian, J.-J., 鈥� Van Etten, R. A. (2019). Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms. Hematological Oncology.
- Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
  Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2019). Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine.
- Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist
  Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., 鈥� Ohgami, R. S. (2019). Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 41(3), 345鈥�52.
- MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells.
  Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., 鈥� Felsher, D. W. (2019). MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Research.
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
  Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., 鈥� Passamonti, F. (2018). Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. BLOOD CANCER JOURNAL, 8.
- A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
  Gotlib, J., Baird, J. H., George, T. I., Langford, C., Reyes, I., Abuel, J., 鈥� Verstovsek, S. (2019). A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Advances, 3(15), 2264鈥�71.
- Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.
  Zhang, H., Wilmot, B., Bottomly, D., Dao, K.-H. T., Stevens, E., Eide, C. A., 鈥� Tyner, J. W. (2019). Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood.
- TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis
  Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., & Hartmann, K. (2019). TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis. LABORATORY INVESTIGATION, 99.
- TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis
  Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., & Hartmann, K. (2019). TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis. MODERN PATHOLOGY, 32.
- World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
  Shomali, W., & Gotlib, J. (2019). World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology.
- MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
  Jawhar, M., Schwaab, J., 脕lvarez-Twose, I., Shoumariyeh, K., Naumann, N., L眉bke, J., 鈥� Reiter, A. (2019). MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900640.
- Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group.
  Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., 鈥� Passamonti, F. (2019). Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group. American Journal of Hematology.
- A Kindred with a 脽-Globin Base Substitution [脽89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.
  Shomali, W., Brar, R., Arekapudi, S. R., & Gotlib, J. R. (2019). A Kindred with a 脽-Globin Base Substitution [脽89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt. Hemoglobin, 1鈥�4.
- International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
  Sperr, W. R., Kundi, M., Alvarez-Twose, I., van Anrooij, B., Oude Elberink, J. N., Gorska, A., 鈥� Valent, P. (2019). International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. The Lancet. Haematology.
- PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
  Verstovsek, S., Hasserjian, R. P., Pozdnyakova, O., Veletic, I., Mesa, R. A., Foltz, L., 鈥� Gotlib, J. R. (2018). PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. BLOOD, 132.
- Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.
  Kluin-Nelemans, H. C., Reiter, A., Illerhaus, A., van Anrooij, B., Hartmann, K., Span, L. F., 鈥� Sperr, W. R. (2019). Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia.
- New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.
  Arock, M., Sotlar, K., Gotlib, J., Sperr, W. R., Hartmann, K., Schwartz, L. B., 鈥� Valent, P. (2019). New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leukemia & Lymphoma, 1鈥�9.
- Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
  Dao, K.-H. T., Gotlib, J., Deininger, M. M., Oh, S. T., Cortes, J. E., Collins, R. H., 鈥� Tyner, J. W. (2019). Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900895.
- New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis.
  Reiter, A., George, T. I., & Gotlib, J. R. (2020). New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis. Blood.
- Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification.
  Trizuljak, J., Sperr, W. R., Nekvindov谩, L., Oude Elberink, H., Gleixner, K. V., Gorska, A., 鈥� Valent, P. (2020). Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification. Allergy.
- Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
  Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O'Connell, C., 鈥� Mascarenhas, J. (2020). Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood.
- MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
  Jawhar, M., Schwaab, J., Alvarez-Twose, I., Shoumariyeh, K., Naumann, N., Luebke, J., 鈥� Reiter, A. (2020). MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. ONCOLOGY RESEARCH AND TREATMENT. KARGER.
- Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology.
  Ozturk, K., Cayci, Z., Gotlib, J., Akin, C., George, T. I., & Ustun, C. (2020). Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. Blood Reviews, 100693.
- Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
  Hartmann, K., Gotlib, J., Akin, C., Hermine, O., Awan, F. T., Hexner, E., 鈥� Kluin-Nelemans, H. C. (2020). Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. The Journal of Allergy and Clinical Immunology.
- Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
  Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., 鈥� Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1鈥�8.
- Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions.
  Valent, P., Akin, C., Bonadonna, P., Brockow, K., Niedoszytko, M., Nedoszytko, B., 鈥� Hartmann, K. (2020). Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions. The Journal of Allergy and Clinical Immunology.
- Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
  Coltoff, A., Mesa, R., Gotlib, J., Shulman, J., Rampal, R. K., Siwoski, O., 鈥� Mascarenhas, J. (2020). Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clinical Lymphoma, Myeloma & Leukemia.
- Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.
  Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., 鈥� Galli, S. J. (2020). Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 10(23), 10743鈥�68.
- Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.
  Ustun, C., Morgan, E. A., Ritz, E. M., Vestergaard, H., Pullarkat, S., Kluin, P. M., 鈥� Marcucci, G. (2020). Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology.
- Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
  Gerds, A. T., Gotlib, J., Bose, P., Deininger, M. W., Dunbar, A., Elshoury, A., 鈥� Sundar, H. (2020). Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(9), 1248鈥�69.
- Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
  McLornan, D., Mesa, R., Catalano, J., Cervantes, F., Devos, T., Egyed, M., 鈥� Kowalski, M. (2020). Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
  Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., 鈥� Sundar, H. (2020). Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(10), 1385鈥�1415.
- Practical Management of Adverse Events in Patients With Advanced Systemic Mastocytosis Receiving Midostaurin.
  Gotlib, J., Kluin-Nelemans, H. C., Akin, C., Hartmann, K., Valent, P., & Reiter, A. (2020). Practical Management of Adverse Events in Patients With Advanced Systemic Mastocytosis Receiving Midostaurin. Expert Opinion on Biological Therapy.
- Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
  Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., 鈥� Sperr, W. R. (2021). Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. THERANOSTICS, 11(1), 292鈥�303.
- Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia.
  Jain, J., Weinzierl, E. P., Saxe, D., Bergsagel, J., Gotlib, J., Reiter, A., & Raikar, S. S. (2020). Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia. HemaSphere, 4(6), e486.
- Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin.
  Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., 鈥� Valent, P. (2020). Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. The Journal of Allergy and Clinical Immunology. In Practice.
- Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors
  Wernig, G. (2021). Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences, 118 (2)(Jan 2021).
- Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
  Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., 鈥� Sperr, W. R. (2021). Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 11(1), 292鈥�303.
- Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.
  Cui, L., Moraga, I., Lerbs, T., Van Neste, C., Wilmes, S., Tsutsumi, N., 鈥� Wernig, G. (2021). Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences of the United States of America, 118(2).
- What your HalphaT says about you.
  Gotlib, J. (2021). What your HalphaT says about you. Blood, 137(2), 151鈥�53.
- Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
  Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., 鈥� Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1鈥�6.
- Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
  Mu帽oz-Gonz谩lez, J. I., 脕lvarez-Twose, I., Jara-Acevedo, M., Zanotti, R., Perkins, C., Jawhar, M., 鈥� Orfao, A. (2021). Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. The Lancet. Haematology.
- Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM).
  Aberer, E., Sperr, W. R., Bretterklieber, A., Avian, A., Hadzijusufovic, E., Kluin-Nelemans, H. C., 鈥� Valent, P. (2021). Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). The Journal of Investigative Dermatology.
- Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.
  Gotlib, J., George, T., Carter, M. C., Austen, K. F., Bochner, B., Dwyer, D., 鈥� Akin, C. (2021). Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. The Journal of Allergy and Clinical Immunology.
- Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
  Shomali, W., & Gotlib, J. (2021). Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. International Journal of Molecular Sciences, 22(6).
- COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
  Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H. O., Akin, C., Nedoszytko, B., 鈥� Valent, P. (2021). COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). The Journal of Allergy and Clinical Immunology. In Practice.
- Avapritinib induces responses in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapy
  Radia, D., Drummond, M. W., Gotlib, J., George, T. I., Quiery, A. T., Winton, E., 鈥� DeAngelo, D. J. (2021). Avapritinib induces responses in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapy. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.
- A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
  Oh, S., Kiladjian, J.-J., Palandri, F., Gotlib, J., Mohan, S., Ali, H., 鈥� Verstovsek, S. (2021). A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). BRITISH JOURNAL OF HAEMATOLOGY. WILEY.
- Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
  Han, S. Y., Mrozek, K., Voutsinas, J., Wu, Q., Morgan, E. A., Vestergaard, H., 鈥� Yeung, C. C. (2021). Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 5(10), 2481鈥�2489.
- Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis
  Radia, D. H., Sabato, V., Castells, M., Akin, C., Elberink, H. O., Tashi, T., 鈥� Gotlib, J. (2021). Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.
- Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
  Taylor, F., Li, X., Yip, C., Padilla, B., Mar, B., Green, T., 鈥� Gotlib, J. (2021). Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). Leukemia Research, 108, 106606.
- Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
  Tremblay, D., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., 鈥� Mascarenhas, J. (2021). Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research, 109, 106629.
- Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
  Naumann, N., Lubke, J., Shomali, W., Reiter, L., Horny, H.-P., Jawhar, M., 鈥� Schwaab, J. (2021). Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology.
- Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.
  Gulen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., 鈥� Valent, P. (2021). Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. The Journal of Allergy and Clinical Immunology. In Practice.
- Diagnosis and management of neutrophilic myeloid neoplasms.
  Schwede, M., Gotlib, J., & Shomali, W. (2021). Diagnosis and management of neutrophilic myeloid neoplasms. Clinical Advances in Hematology & Oncology : H&O, 19(7), 450鈥�459.
- Diagnosis and Management of Neutrophilic Myeloid Neoplasms
  Schwede, M., Gotlib, J., & Shomali, W. (2021). Diagnosis and Management of Neutrophilic Myeloid Neoplasms. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19(7), 450鈥�459.
- PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM).
  DeAngelo, D. J., Reiter, A., Radia, D., Deininger, M. W., George, T. I., Panse, J., 鈥� Gotlib, J. (2021). PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
  Oh, S. T., Kiladjian, J.-J., Palandri, F., Gotlib, J. R., Mohan, S., Ali, H., 鈥� Verstovsek, S. (2021). A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Current and future status of JAK inhibitors
  McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021). Current and future status of JAK inhibitors. LANCET, 398(10302), 803鈥�816.
- A novel activating JAK1 mutation in chronic eosinophilic leukemia.
  Shomali, W., Damnernsawad, A., Theparee, T., Sampson, D., Morrow, Q., Yang, F., 鈥� Gotlib, J. R. (2021). A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood Advances.
- Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
  Chen, J. A., Hou, Y., Roskin, K. M., Arber, D. A., Bangs, C. D., Baughn, L. B., 鈥� Gotlib, J. (2021). Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Advances, 5(17), 3492鈥�3496.
- Efficacy and Safety of <= 200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies
  Radia, D., DeAngelo, D., Deininger, M. W., Reiter, A., Sen, J., Lin, H. M., 鈥� Gotlib, J. (2021). Efficacy and Safety of <= 200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment
  Reiter, A., Cross, N. C. P., & Gotlib, J. (2021). Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Chronic Eosinophilic Leukemia: Diagnosis and Therapy
  Gotlib, J., Shomali, W., & Reiter, A. (2021). Chronic Eosinophilic Leukemia: Diagnosis and Therapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management.
  Shomali, W., & Gotlib, J. (2021). World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology.
- Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
  Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., 鈥� Valent, P. (2021). Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia.
- Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms
  Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., 鈥� Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. CELL REPORTS MEDICINE, 2(10).
- Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.
  Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., 鈥� Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Reports. Medicine, 2(10), 100425.
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
  Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., 鈥� Metcalfe, D. D. (2021). Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HEMASPHERE, 5(11).
- Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
  DeAngelo, D. J., Radia, D. H., George, T. I., Robinson, W. A., Quiery, A. T., Drummond, M. W., 鈥� Gotlib, J. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine.
- Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
  Gotlib, J., Reiter, A., Radia, D. H., Deininger, M. W., George, T. I., Panse, J., 鈥� DeAngelo, D. J. (2021). Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine.
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.
  Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., 鈥� Metcalfe, D. D. (2021). Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 5(11), e646.
- Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.
  Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., 鈥� Sakamoto, K. M. (1800). Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 13(24).
- Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
  Lubke, J., Schwaab, J., Naumann, N., Horny, H.-P., WeiSS, C., Metzgeroth, G., 鈥� Reiter, A. (2022). Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2101849.

View More Publications

Clinical Trials

Clinical trials are 糖心传媒 studies that evaluate a new medical approach, device, drug, or other treatment. As a 糖心传媒 patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Closed Trials

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Specializing In

Chronic Myelomonocytic Leukemia
Leukemia
Multiple Myeloma

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Palo Alto, CA

Hematologic Cancer Program

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of 糖心传媒, 糖心传媒 Tri- Valley, or Stanford Medicine Partners. 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(65 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Review Summary

Dr. Gotlib is known for his thoroughness and attentiveness to patient concerns. He is regarded as knowledgeable and an excellent communicator. Many appreciate that he listens carefully, provides clear guidance, and ensures all questions are answered. Patients express feeling cared for and comfortable under his care, valuing his expertise and the time he takes to understand their individual needs.

The summary was created by AI, based on recent patient reviews. Learn more

Patient Reviews

(372 reviews)

Dr. Gotlib is the best Myelofibrosis Specialist he really helped me understand my present condition

Jul 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He listens, and takes as much time as necessary, in addition the is expert in my husband芒鈧劉s disease, and knows latest treatmenta

Jun 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An Extraordinary physician and excellent diagnostician

Jun 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor

May 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent specialist and great mannerism

Apr 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Experienced professional who tells it like it is.

Mar 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib, MD is outstanding!!

Feb 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He's the best kind of doctor you could hope for. Very through and thoughtful. gives clear guidance and direction. Never rushes you. Has excellent specific knowledge about my particular cancer and that is extremely valuable to me. I can't say enough good things about him. We need many more Dr Gotlibs in the world. Lucky me that I'm one of his patients.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I felt he was very engaged, thoroughly answered all questions and addressed all related issues. I felt very comfortable talking to him and wish I could see him as a patient in the future.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A knowledgeable doctor whose care plan is based on knowledge and understanding the patient. He listens to the patient

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I believe Dr. Gotlib is an excellent, and caring doctor. I find him easy to communicate with, and feel that he understands, and cares about me and my illness.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I just really appreciate how Dr Gotlib listens to my concerns and solves the problems immediately. He reviews everything about me and I feel really cared for.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib is an excellent doctor.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s an amazing doctor, so grateful to be under his care

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An excellent and caring physician.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is the best specialist with whom I have ever worked. He is kind, he is present and always listens carefully. He asks great questions. He is always encouraging. While I always defer to his medical judgment and suggestions, I find him very open minded and genuine. In my experience this is rare and I am very grateful. I place tremendous trust in his expertise and he holds an extremely important position as one of the most important member of my care team.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have been seeing Dr. Gotlib for over a decade now and he's really the best. I have the highest confidence in him both as a person and as a medical doctor.

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very thorough and understands my issue very well. He is very easy to communicate with.

Nov 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was very thorough. He went over lab results and medications. He answered questions. He confirmed my next appointment to be in-person, along with an MRI. I am very pleased with Dr. Gotlib and his care for me.

Nov 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am so thankful that he芒鈧劉s my doctor

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is amazing, I appreciate his attentiveness!

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib listens closely to my concerns and always provides possible solutions, as well as concerns. With his expertise, I am able to navigate general health concerns which my cancer has impacted, I芒鈧劉m thankful he plays a part in my well-being and my cancer journey.

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very knowledgable and personable. I feel very comfortable with him personally during appointments and also I feel like I am in very good hands when assessing my condition. highly recommend.

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is excellent. Really a good communicator.

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

excellent doctor

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and Dr. Kaplan were extremely thorough, professional, and showed genuine concern

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a caring and knowledgeable hematologist. I feel extremely fortunate and happy that he is my doctor.

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib has been an amazing partner for me in my CML journey, and I feel lucky to have him as a doctor. He's been very attentive with my labs, so I'm thankful to have him followup on certain items

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very thorough, professional, knowledgeable and kind. I have referred others to him.

Aug 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is outstanding! Listens very well asked great questions and is totally up on all the 糖心传媒 for my condition.

Aug 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is highly skilled in his field, empathic, and thorough. His has a wonderful demeanor.

Aug 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib cares about the patient

Aug 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib was very helpful and I芒鈧劉m pleased that he has adjusted my medication

Jul 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very approachable and listens, someone always answers email He is very knowledgeable about Dino芒鈧劉s disease.

Jul 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is outstanding! His keen expertise, abundant compassion and patience are exemplary. I have complete confidence in his medical knowledge and in his ability to care for my health.

Jul 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I芒鈧劉m very fortunate to have him handling my case!

Jul 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A very understanding physician who listens and is able to fully explained his decisions.

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is excellent, he follows up with appointments and he checks all the patient chart before to have precise topics and information.

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very good at understanding the illness and how to control it.

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is an outstanding, astute, empathic, amazing hematologist. I芒鈧劉m so grateful to be able to work with him.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He's an amazing, caring doctor and I'm fortunate to be his patient. His concern for my quality of life as well as health issues is extraordinary.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent doctor. Very happy that he is monitoring my health.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

It was a very nice visit. He was relaxed and attentive and thorough. I don芒鈧劉t have anything negative to add.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am very lucky to have him as my physician.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent bedside manner.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you Dr z Gotlib for 芒鈧搒eeing芒鈧� me, genuinely caring about me. It matters.

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is a wonderful, caring, knowledgeable doctor and MPN Specialist and I am so grateful that I found him and to be under his care.

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I芒鈧劉ve been seeing Dr Gotlib for about 7 years. He always takes my health seriously and answers all my questions. He芒鈧劉s the best doctor i see in my life

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib covered thoroughly my concerns.

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is the best. I look forward every year to our visit.

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank You!

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He listens and gives us plenty of time for questions. We can also email or call him if necessary. Our Primary oncologist from Kaiser can consult with him if necessary. We are glad that our Kaiser Hematologist ( who has since left Kaiser) recommended him.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason's a wonderful doctor who I appreciate very much.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I appreciate his patience in listening to my questions and answering each of them thoroughly. I did not feel rushed during my visit.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent, caring physician and I am glad to have him as my doctor,

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent Doctor great communication, detail oriented, and fun. On a video visit, Dr. Gotlib provides the same care and concern as if it was an in person visit. I highly recommend him. Thank you.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I will repeat part of my last answer. Dr. Jason Gotlib is an excellent doctor in all ways. He is clearly on top of all aspects of his specialty. He is kind and interested and makes me feel completely comfortable. He speaks to me like an equal. I have complete confidence in him and his suggestions for my care.I could not be happier to have him for my doctor.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a good listener, he explains everything in details and he is patient to answer questions and make the patient comfortable to share symptoms and fears about the desease. I appreciate so much him and his team, they are fast to answer messages in the portal and they make sure I will have the care I need.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am always grateful to that Dr Gotlib is on my team. His calm, practical, and methodical approach is reassuring and calming.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We are honored to have him as my doctor.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Many thanks to Dr Gotlib

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s wonderful. Knowledgeable and compassionate

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel very confident in my care with Dr. Gotlib. He is not only extremely competent but also very kind. I am most grateful having him as my doctor as I know that he is one of the foremost experts in the field and I am honored to have him in charge of my care. I am fully aware that many people have to travel long distances to have an authority in MPN's available to follow their care, therefore I am truly blessed to have Dr. Gotlib leading my journey with Essential Thrombocythemia. I couldn't do it without him. Thank You Dr. Gotlib !!!

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is an excellent physician and I feel extremely fortunate to have him as my hematologist.

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is very patient, kind, and empathetic

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I'm thankful for Dr Gotlib, and completely respect his opinion and caring nature

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is excellent and knows his patients well and provides clear instructions as needed.

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very great experience, Dr. Gotlib listened to our questions and answered all. Thank You.

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Amazing doctor!!!

Dec 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib, MD is a kind, compassionate and deeply knowledgeable hematologist. I completely trust Dr. Gotlib to provide me with the best medical care.

Nov 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor!

Nov 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib, is very good at explaining all my concerns, aside from being Highly Intelligent, Great beside manner, funny and Handsome he's very Interesting.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am thankful every day that Dr. Gotlib is in my care team!

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A wonderful doctor!

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Professional direct and very knowledgeable

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a great doctor, I feel honored and privileged to be his patient. I feel absolutely confident that Dr Gotlib will do everything possible to help me with my health issues.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am grateful to be in Dr. Gotlib's care.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is an expert amd we are grateful to have him see me.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I appreciate Dr. Gotlib, and highly respect his opinion and advice.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He's brilliant, informed, personable, engaged, and totally patient-focused during visits.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very comfortable to talk with very thorough, very professional, and very much informative and knowing about my essential thrombocythemia He gave me hope which I am so thankful for

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is an excellent Dr and I am grateful I am under his care.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib explained everything and answered all my questions. I felt a lot more comfortable with my diagnosis after speaking to him.

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great Doc, very thorough and I never feel rushed.

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an exceptional doctor, both in skill and knowledge but also compassionate and really interested about all that is going on in my life and even integrates that into his notes of the visit. It shows that he really pays attention to me. He offers me options and then we come up with a plan and I know I can reach out to him at any time in order to ask a question or to review things for me.

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Jason Gotlib has been a wonderful professional in this field, he answers all of my questions and has always been candid with me. Thank You JG

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

As always, I completely trust Dr. Gotlib, and his knowledge. I feel like he is there for me, and genuinely cares for his patients.

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you so very much, I couldn't have done it without you 芒陇茂赂

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s an awesome doctor and explain things very clearly so I understand it. Not all of us are doctors who is this or laymen try and understand what芒鈧劉s going on. That芒鈧劉s why he芒鈧劉s the best those practice.

Jul 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He made me feel like I WASN芒鈧劉T wasting his time and that my concerns were valid. He gave me hope.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a very caring and informative Doctor with amazing credentials.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

One of the very best in his field..

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best!

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A wonderful doctor with great assistants.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

dr. Gotlib is an excellent and caring physician. I feel fortunate to be his patient.

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is the best!

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a great Doctor. Grateful to have as my MPN specialist

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent provider. He's well-informed, accessible, curious about me as a patient and my experiences.

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is always awesome, he always answers my questions and asks questions to find out how I am doing. I am very happy Jason Gotlib is my Doctor.

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Fantastic doctor and expert. Honored to have him look at my case.

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is an excellent communicator when his audio is working better. (I am also slightly hard of hearing.)

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

the specialist that I see is very knowledgable in the specific medical condition that I have

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Fortunately for me, Dr. Gotlib is an MPN Specialist and I was lucky to meet him at a MPN Symposium that he spoke at. He is not only extremely knowledgeable and thorough he is kind, understanding and a good listener. I really appreciate how accessible he is through Stanfords website as he and his staff always get back to me quickly when I reach out to them. I attribute the fact that I am doing so well with my illness to Dr. Gotlib and I highly recommend him to others in my MPN Support Group.

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very understanding, and certainly speaks so that I could understand what he was telling me. He answered all my questions.

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He has a good 芒鈧揵edside芒鈧� manner and listens to our concerns. We never feel like we are rushed.

Mar 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Loved that he thought all my questions were good questions. I felt he listened very well and provided satisfactory answers.

Mar 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Looking forward to meeting Dr Gotlib in person next month.

Mar 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I was very pleased with my first appointment, I have seen other hematologist in Stanford also, but this time it was a remarkable experience for me.

Feb 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib has been treating me since 2018. I am so happy that he was recommended to me!

Feb 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is caring and knowledgeable. I'm glad he's my doctor, and appreciate him every day.

Feb 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We think he is the best and has the best staff. He is easy to talk to and easy to understand. We appreciate all he does.

Feb 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a great doctor and explains everything clearly. I recommend him to anyone with the same circumstances.

Jan 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent

Jan 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a wonderful time and again I very much appreciate his time and his expertise. Honored to be a patient of his

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He provided me with excellent information.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent care!!!

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have great respect for Dr Gotlib and his 糖心传媒 in

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very knowledgeable in MPNs, so I was glad to be able to talk to him today.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is an outstanding physician. I am so deeply grateful he is my hematologist. His expertise, keen intellect, kindness and compassionate listening skills are just a few of his remarkable qualities. I am able to fully trust Jason Gotlib with my care. Thank you.

Nov 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s a great doctor

Nov 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best in this disease area. He saved my life with the innovative medicine which he has developed the concept and details over years

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Organized Detailed Precise Provided valuable information And outline a plan of action for my care Well spoken

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thanks for the cordial and informative meeting!

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you so very much Dr. Gotlib, I surely appreciate the time you allow for my case.

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you for clarifying 芒鈧揷ure芒鈧� from remission.

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor and person

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s awesome and I appreciate his expertise. Knowing he芒鈧劉s in my corner is a big plus for me mentally.

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I芒鈧劉m very happy with Dr. Gotlib, very grateful he is my doctor.

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An excellent doctor!

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The Dr was very attentive and answered most of my questions before I even asked them. He quickly digested the info provided by his assistant and asked appropriate questions. He developed a plan of action 芒鈧搊n the fly芒鈧� and he seemed genuine in his approach. I also appreciated his sense of humor. As an aside, I particularly liked the pre-visit with the assistant which thereby allowed the Dr. More time to focus on my illness and a treatment plan. The assistant was also very kind and professional.

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib was outstanding. He was informative, knowledgeable and friendly. I enjoyed seeing and being seen by Dr Gotlib.

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is such a knowledgeable, thorough Physician that goes through every bit of my recent history and lab work. He cares about what is going on in my life, we laugh, and makes the visit that much more pleasant. And then there is always a plan for the future in place so I never feel unsupported.

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib took over my clinical trial after Dr Coutre passed away. He has been kind and patient with me as I processed the change. He has addressed any and all of my questions and concerns thoroughly and in a timely manner. I am very thankful for him to be coordinating my care.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Exemplary.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

As I have grown accustom to, it is always a pleasure to meet with Dr Gotlib - his care is excellent and I feel blessed to have him as my Dr.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I so appreciate the time he takes to explain away even the slightest concern I have, it is very reassuring!

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is a caring and knowledgeable doctor. I feel like he is there for me.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

very pleasant encounter and helpful telephone visit.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best doctor I芒鈧劉ve ever met who saved my life. He芒鈧劉s the best in his field

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent visit with new insights into my condition and plans for future care.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Outstanding.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I was referred to Dr. Gotlib by my brother芒鈧劉s step son who is a Hematologist practicing in Tampa, Fl., Thank Goodness Dr. Gotlib was accepting new patients, and I believe I芒鈧劉m very lucky to be advised and cared for by this doctor.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I know he's very busy-appreciated his time.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very compitent dr and very personable

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib was great had a great conversation

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib is outstanding. He is a perfect blend of extreme expertise, compassion, patience and caring. I am so very grateful to have him as my hematologist.

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is a wonderful doctor. I feel well cared for and completely informed. He is at the top of his field and I am grateful for his care. Joyia Felice

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor!

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best doctor I芒鈧劉ve ever met. His innovations have been saving lives of thousands of thousands of patients, who otherwise would have suffered a lot of bad symptoms of the diseases and died in a very short time

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am grateful to have access to his expertise, care and recommendations. I appreciate his assistance in helping me cope with my disease and how to handle interfacing with other physicians as it pertains to how my hematological disease and treatment interact with my other medical conditions.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Caring and understanding, I feel like he's there for me.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Greatest Doctor ever , period !!! And a real human person ...

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s a great dr, very professional and caring. I really like him

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very knowledgeable and down to earth

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great visit. Thank you!

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Personable caring Dr.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is a very caring doctor. He answered all my questions so I could easily understand. And, he clearly stated what should happen next and when. He projects warmth and genuine concern for his patients.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I appreciate his style, gets to the point, ask the necessary questions, and listens well. It was a pleasure to meet him.

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I was certainly impressed with Dr.Gotlib. He has taken over a very important position and I wish him well.

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a rock-star!

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An extremely caring and attentive, knowledgeable physician. The empathy and patience he demonstrates are remarkable.

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Best physician I have ever seen

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is beyond excellent !!

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you!!!!

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s the best and saved my life

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Caring, personable doctor

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and his staff are always very professional and helpful

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We highly respect Dr. Gotlib and his expertise in my husband芒鈧劉s condition. He is always professional and listens to our concerns. He has a good manner with his patients.

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib IS an excellent professional specially in the hematology field.

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you for your time!

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is brilliant and compassionate.

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Always have great experiences with Dr Gotlib, nothing but high marks for him

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was very compassionate, listened to me, and answered all of my questions and concerns. He also was very clear on explaining what tests and procedures he would like me to have done, and why they would be helpful to him to help me. I was very impressed by Dr Gotlib.

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I l liked he was very convinced oh. I liked his bedside manner

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Exemplary in all respects.

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was very clear and helpful. I am grateful for his help.

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Looking forward to seeing you in April when the latest virus wave passes.

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

HE CONTINUES TO BE AN EXCELLENT LISTENER, PROBLEM SOLVER, PHYSICIAN AND PERSON.

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best

Jan 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is personable and seems genuinely interested in my condition and how I am doing. He is also able to answer my questions re: "the science" and possible future treatment options, which is a topic I am very interested in. He provided timely follow-up to my questions/lab tests using MyChart.

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor. Takes his time during office visits.

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was respectful, understanding, and excellent!

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Listens carefully, feels like he truly cares, very knowledgable. Feel confident in his care.

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel safe we芒鈧劉ll cared for in this office My dr and staff are top notch in knowledge and care

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I like Dr. Jason Gotlib very Much. He is excellent!!

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a Genius

Dec 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason is an outstanding hematologist. He is caring, patient and extremely knowledgeable about my blood cancer. He is also generous with his time, even following my appointment, making himself available through the Stanford My Health app. His expertise and compassion are a rare and valuable gift. I芒鈧劉m so grateful to have him as my hematologist.

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a wonderful doctor, very thorough and caring.

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is excellent

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very smart and knowledgable and pleasant.

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is a very nice person and I feel very comfortable speaking with him.

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib answered all of my questions and gave as much of his time as I needed. I came away from my meeting with Dr Gotlib reassured about my prognosis and management path. I can芒鈧劉t say enough good things about Drs Gotlib and Eckhert.

Nov 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr, Gotlib was very clear and direct but also sensitive and considerate. I appreciated the frank nature of his approach and the details of the explanations balanced with a kindness and patience I am sure is challenging given his level of expertise and the simple nature of my level of questions.

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel like he will cure me and I thank for that.

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

As I've said..I'm very pleased.

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Appreciated Dr Gotlib''s friendly and informative manner

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

excellent visit

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s the best and his years of medical work helped start the nee treatment of Mastocytosis. I芒鈧劉ve been seeing Dr Gotlib for over four years and he has provided me the optimal treatment plan. He has also given me tons of care, not treating my disease but taking care my whole health. He芒鈧劉s a top KOL in this field and his 糖心传媒 saved many people芒鈧劉s lives. I do like him!

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent appointment, no problems

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We moved to Los Angeles in 2020 so the most convenient and safest way for me to have care appointments with Dr. Gotlib at this point is in video format. I'm very grateful that Stanford offers this option. As long as my symptoms have not changed, and as long as my local UCLA Hematologist monitors my medication needs and blood counts, I am content to continue to see Dr. Gotlib in this way. Thank you for making it so easy to have Dr. Gotlib as a critical member of my care team.

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Perfection !

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is incredible. He's extremely knowledgeable, compassionate and patient. I always have the sense that he has the most advanced and accurate information and treatment. He always seems to make time to hear all of my concerns and is easy to talk with.

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very professional.

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Goltlib is extremely good at explaining bot what and why we are pursuit a treatment. I feel that he cares

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a fine physician and great human being!

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor. Thank you!

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib is an outstanding physician. He not only provides excellent care, he is also compassionate and a good listener. I feel secure knowing that I am under his care.

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent. He answered my questions and he provided some "Possible" avenues of treatment. His attitude was very inspiring and helped to ease some of my anxiousness over my situation.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s the super doctor who saved my life. I believe his 糖心传媒 and leading all the clinical trials will finally benefit millions of patients

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was excellent! He asked about goals for the consultation up front. Patiently explained things and answered all of our questions. We are very grateful to have the benefit of his high level of expertise.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Exemplary!

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent doctor with whom i find it very easy my medical issues.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is an excellent Dr. He is so knowledgeable and has a great way of putting me at ease over my blood disorder. No question goes unanswered and he is always positive, even when he is clarifying lab work for me. He is a wonderful asset to the Stanford team.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s very friendly and knowledgeable about the diseases and he teaches you more about living with the condition. He is overall a great doctor

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is excellent.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very patient and helpful in answering all of our questions and involves me in the decisions about my health care.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is extremely thorough and patient. I appreciate him taking the time to go over all aspects and options for my care. Truly a wonderful doctor and I芒鈧劉m grateful to have him as my specialist.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent physician and clearly cares about me. HIs assistants are always knowledgeable and courteous. I am entirely happy with his care and feel lucky to have him as my doctor.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is my favorite doctor.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Appreciate his time and expertise.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an empathetic doctor who is especially good at listening. He is always willing to help with patient needs.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and his "Fellow" were excellent in communicating and giving me verbal feedback...call went smoothly.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I芒鈧劉m thankful you have an expert on my rare blood disorder that is leading 糖心传媒 in blood disorders. Very appreciative of his time

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very professional and I'm very confident I am getting great care from him.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib is the best!!

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is personable, he listens to my concerns and answers them so I understand. He is professional but remembers my history without looking at notes.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib has always been extremely helpful and I am glad he has been my doctor since day 1. He always answers my questions and explains in ways I can understand.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a wonderful brilliant caring doctor

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great physician, very lucky to have him

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor. He answers to all patient's concerns.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor with an abundance of knowledge and open to trying new remedies.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Awesome!!!

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel extremely fortunate to have Dr. Gotlib as my Physician.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He provided the information we needed to make a very hard decision about care and treatment going forward. As I stated earlier, although delivering difficult information, he showed nothing but kindness and compassion.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I find Dr Gotlib to be very compassionate and invests the time necessary to address my questions and concerns. I would highly recommend Dr. Gotlib if ever asked.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A wonderful caring physician who explains everything clearly.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very knowledgeable and offered several options for my concerns.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very caring and compassionate. He had reviewed my medical records prior to the visit which I greatly appreciated. I also felt he gave great thought to my case. The staff setting up the appointment was excellent. Highly recommend!!

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very caring and interested in the patient.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you so much for your care.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very confident in him!

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very caring, excellent doctor.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Wow, He was highly recommended to me and I see why. I feel much better being in his care. Thank you

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and his staff are always caring and professional.

Mar 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Doctor Gotlib is polite, considerate and friendly. He is the finest medical professional I have ever met.

Jan 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He talked to me, not down to me and used terms I would understand.

Nov 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An excellent doctor and a warm, compassionate, caring person. I'm fortunate to be his patient -

Oct 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Gotilb is the best.

Sep 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib, and all the members of his team were amazing. Dr. Gotlib explained things in a manner that I could easily understand.

Apr 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib took the time to listen to my concerns and explained in terms that I could understand potential therapies and my prospects. He is an accomplished professional who inspires confidence.

Feb 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib and his assistants are the best I've ever had. I always feel great after my visits, because they give me hope. They obviously care and Dr Gotlib has a wonderful "bedside manner".

Feb 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib is excellent.

Jan 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

They have always been amazing they are always on top of the med and tests I'm always caught up.

Jan 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel very fortunate to have the benefit of this doctor's experience and expertise, given the rarity of my disease process.

Dec 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib is always kind and caring.

Dec 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very fortunate to have Dr. Gotlib and staff.

Nov 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Was timely visit. Given the state where I am with my condition there was not much advice given for me to follow.

Oct 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib has always taken the best care with me.

Oct 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. J. Gotlib is excellent. The fellow with him was also caring.

Sep 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is EXCEPTIONAL. An ideal physician.

Sep 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Both the fellow in hema./onco. and Dr. Gotlib were quite easy to talk to.

Sep 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is excellent, both in terms of expertise and "bedside manner." I'm very grateful to have access to such good care.

Sep 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Outstanding care provided by Dr. Gotlib to me, as well as care provided by entire team.

Aug 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We love Dr. Gotlib and feel so fortunate to have found him. He and his staff are super-competent and caring - we trust them completely.

Jun 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is exceptional. Brilliant, yet approachable. Professional yet warm. V. caring. He has restored my health. He didn't have the answer for what was wrong with me. However he had ideas for how to get the answer.

Jun 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Stanford Health is a wonderful full care center. I hope to visit there again.

May 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

My friend who drove me was also impressed.

Apr 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have nothing but great things to say about Dr. Gotlib, William and the entire staff. I have total confidence in them.

Mar 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Jason Gotlib MD is the most compassionate and excellent doctor - He truly listens to my concerns and gives his expertise advise on the management of my disease.

Feb 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All good experience. I feel very comfortable under Dr. Gotlib & Co. care.

Jan 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very lucky to have a great doctor as well as his staff.

Dec 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Best physician EVER!

Nov 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib spent lots of time with me. Walked away with more questions, but will email him with them.

Nov 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All 3 team members extremely competent and caring, gave through answers & explanations.

Nov 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib always has a smile and makes you feel you're his only patient. Answers my questions in a way I can understand.

Sep 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is outstanding in every way.

Aug 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel v. fortunate to be a patient of Dr. Gotlib.

Aug 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is outstanding!!

Jul 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent & caring.

Jul 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib & Len are amazing, empathetic, & caring. I love them.

Jul 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I primarily commend my doctor, Dr. Jason Gotlib, for the outstanding care he has been giving me.

Jun 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

That they attended me well.

May 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib & Dr. Hollenhorat were both excellent. I am so glad I made the 4 1/2 hr. trip to Stanford.

Mar 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very good and very happy.

Feb 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent.

Feb 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib - an exceptional doctor.

Jan 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is very thorough and listens and shows concern. He is the best and I would recommend to anyone who needs a good dr.

Jan 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Generally excellent.

Dec 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib does a great job.

Nov 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an exceptional doctor - Lucky to have found him and under his care.

Nov 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctors who do a thorough exam and explanation of labs. Great listeners. Always a pleasure.

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I highly recommend Dr. Jason Gotlib - his approach, his kindness and knowledge is priceless.

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib interacted with me at a level commensurate w/my education (PhD). It was a welcome new experience for me in the US healthcare system.

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent interaction with Dr. Gotlib, and his fellow Dr. Shomall.

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and the entire staff that I interfaced with were exceptional. Very caring & professional in all areas.

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Professional, courteous, speedy.

Aug 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib (OB) is an excellent doctor. I couldn't ask for better care, thank you.

Jul 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib is unbelievable throughout & explains everything very well. Best doctor I ever had.

Jul 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent - Dr. Gotlib.

Jun 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Total confidence in your staff.

Jun 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Gotlib seems to be on top of his game. Total confidence in him.

Jun 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is terrific and so is his PA.

May 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib has helped me to understand my disorder as well as provided me info to help me manage symptoms.

May 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All very pleasant, professional, efficient!

May 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

This care provider has a very high level of expertise regarding my illness, and he keeps me well informed on all the issues that are relevant.

Apr 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Jason Gotlib & his whole staff are excellent!

Apr 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

糖心传媒 are great and thorough on exams and explaining medicines and labs.

Apr 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I always feel very comfortable with Dr. Gotlieb and staff. My husband and daughter usually go to my appts. with me and also likes the way he talks to us about my condition. Would highly recommend him to others.

Mar 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Wonderful doctor, the very best care.

Feb 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All good - especially good explanation of what is known about my issue.

Jan 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent!

Jan 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have the utmost confidence in Dr. Gotlib. He showed patience & understanding for side-effects I was suffering from.

Dec 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib does a great job taking the time to pay forward attention during my appointments, listening and answering my questions, and providing candid information about diagnosis, tests, and treatments.

Dec 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Lynn NP an Dr.Gatbib have been my "angels" for several years. They are always so sweet and kind and helpful.

Dec 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is a superb doctor and a terrific human being I have been going to him for 9 years.

Nov 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is exceptionally fine at both being personable, caring and knowledgeable.

Nov 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is not only extremely knowledgeable he is also empathetic, courteous, respectful and thorough. I feel SO much better about my condition because I am in his hands.

Nov 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib has been amazing throughout my entire cancer journey. Always compassionate and caring. Thank you!

Oct 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

World-class

Oct 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am very much alive, due to Dr Gotleib and my quality of life is amazing, at 73. Thank yourselves

Oct 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is AMAZING! So friendly, helpful & brilliant!

Sep 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib and his staff could not be better.

Sep 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Good because they explain well about my problem.

Sep 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great job.

Aug 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is great! He's caring. He listens and I feel very confident that he's my doctor.

Jun 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is outstanding, very caring, great with explanations. The very best.

May 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very professional and thorough.

May 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I liked the doctor very much.

May 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All perfect.

May 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlieb was friendly and courteous. Explained what was going on with my medical condition and what we could do to try and keep my health stable. Not only did he talk to me but included my husband and daughter in the conversation.

Apr 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is the best doctor I could have ever hoped for!

Apr 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Both providers where very good. Very happy - - -

Apr 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

No medications but care was all discussed carefully.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

My team of Dr. Gotlib & Lenn Fetcher is exactly what I hope for & need.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I had to ask for the language I can understand without using medical term I'm not familiar with.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Both Dr. Gotlieb & the resident are terrific.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is always an excellent physician. His assistant this day "Lenny" was also an excellent health provider. He was kind, patient, and made me feel at ease. I felt he was more than competent and would trust him with my care. What great care givers I had the honor to have today! Thank you.

Feb 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Felt they really cared.

Jan 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very pleased with Dr. Gotlib's care and professionalism.

Jan 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am grateful to have support and care by Dr. Gotlib and Dr. Beth Martin for systemic mastocytosis.

Jan 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is superb.

Dec 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

It's all good!!! Dr. Gotlib was outstanding with regard to all of the points and much much more - a great professional.

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib's knowledge regarding my disease is excellent and my primary hematologist refers decisions to him.

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Always patient and thorough.

Oct 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Its a good experience.

Sep 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Top notch!

Jul 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Gotlib said he would get my bone marrow sample & retest it. He would contact me. I was not to call him. I paid for bone marrow retest. I have NEVER been contacted.

Jul 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Doctor was attentive & concerned about my condition. Explained things clearly and thoroughly.

Jan 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib's team professionally works together in caring his patient. Dr. Gotlib is one of the best doctor. He's caring, sincere & has an empathetic attitude. That is why his team is as compassionate.

Jan 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I needed a dosage change in my meds. It has been 9 days and have not received new dosage. Disappointed I had to call Stanford, Insight and my ins. co!

Dec 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I'm so glad my life is in their hands.

Oct 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Caring & excellent appt. Whole experience was EXCELLENT - instilled confidence.

Oct 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I think Dr. Gotlib is excellent and feel very comfortable in his care.

Sep 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Everyone shows great knowledge of their duties and responsibilities.

Sep 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Wonderful doctor.

Aug 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlieb is one of the best drs. in country knowing about myelofibrosis.

Aug 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is excellent.

Jul 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is exceptional.

Jul 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib is an excellent dr. & gave his full attention.

Jul 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib has not followed through on any of the next steps. It has been 8 days since my appointment and I am very disappointed in his follow through.

Jul 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very good.

Jun 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

he is worth the wait!

Jun 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel very fortunate to be in the care of Dr. Jason Gotlib.

Jun 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib left me with a sense of hopelessness with minimal treatment options.

Jun 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The doctor and resident dr. were both excellent.

Jun 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have recommended Dr. Gotlib.

Apr 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlieb his student/fellows have always been courteous, attentive, patient and understandingly communicative.

Apr 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Gotlib was not very personable, spoke making eye contact with husband, not me, was abrupt and made me feel foolish at times by dismissing questions.

Mar 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor.

Feb 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone:听1-866-742-4811
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥�5 p.m.

糖心传媒 provides comprehensive services to听refer听and听track patients, as well as the latest information and news for physicians and office staff.听For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

听

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

糖心传媒

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Jason Gotlib

Hematologist-Oncologist

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Publications

Clinical Trials

Specializing In

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Hematologic Cancer Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(372 reviews)

Referring Physicians

PHYSICIAN HELPLINE

糖心传媒

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Jason Gotlib

Hematologist-Oncologist

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Publications

Clinical Trials

Specializing In

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Hematologic Cancer Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(372 reviews)

Referring Physicians

PHYSICIAN HELPLINE